21240-37-9

Basic information

• Product Name: 1,4-Benzenedibutanol
• Synonyms: 4,4'-(1,4-phenylene)dibutan-1-ol;4-[4-(4-hydroxybutyl)phenyl]butan-1-ol;1,4-Benzenedibutanol;4,4-(1,4-Phenylene)bis(butan-1-ol)
• CAS NO: 21240-37-9
• Molecular Formula: C₁₄H₂₂O₂
• Molecular Weight: 222.32328
• Mol File: 21240-37-9.mol

Chemical Properties

• Melting Point: 61-63 °C(Solv: benzene (71-43-2))
• Boiling Point: 387.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.028±0.06 g/cm3(Predicted)
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 1,4-Benzenedibutanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Benzenedibutanol(21240-37-9)
• EPA Substance Registry System: 1,4-Benzenedibutanol(21240-37-9)

Safety Data

• Hazardous Substances Data: 21240-37-9(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
1,4-Benzenedibutanol is used as a chemical intermediate for the production of plasticizers, which are additives used to increase the flexibility and workability of plastics. It is also utilized in the synthesis of resins and other industrial materials, contributing to the manufacturing process of various products.
Used in Environmental and Health Research:
Due to its potential as an endocrine disruptor and its toxic effects on aquatic organisms, 1,4-Benzenedibutanol is a subject of research in environmental and health sciences. Studies on 1,4-Benzenedibutanol help in understanding its impact on ecosystems and human health, guiding regulations and safe handling practices to mitigate potential risks.
Used in Hazardous Substance Management:
As a recognized hazardous substance, 1,4-Benzenedibutanol requires careful management in its handling, storage, and disposal. Industries and laboratories that work with 1,4-Benzenedibutanol must adhere to strict safety protocols and environmental regulations to prevent accidental exposure and environmental contamination.

Upstream product

• 6337-65-1 4-[4-(3-methoxycarbonylpropyl)phenyl]butyric acid methyl ester 
• 85784-83-4 4-[4-(3-Ethoxycarbonyl-propyl)-phenyl]-butyric acid ethyl ester 
• 22339-62-4 4-[4-(3-carboxypropyl)phenyl]butyric acid 
• 624-38-4 para-diiodobenzene 
• 22339-61-3 γ-(p-succinylphenyl)butyric acid 
• 4542-72-7 1,4-bis-(2-bromoethyl)benzene 
• 5140-03-4 2-[4-(2-hydroxyethyl)phenyl]ethan-1-ol 
• 36076-25-2 (4-methoxycarbonylmethylphenyl)acetic acid methyl ester 
• 7325-46-4 1,4-phenylenediacetic acid 
• 134519-88-3 4,4'-(1,4-phenylene)bis(but-3-yn-1-ol) 

Downstream Products

• 2778-48-5 1,4-bis-(4-bromobutyl)benzene 
• 131169-39-6 4,4'-(1,4-phenylene)bis(butane-4,1-diyl)bis(4-methylbenzene sulfonate) 
• 853261-37-7 4,4'-(1,4-phenylene)dibutyl diiodie 
• 832688-84-3 1,4-bis(4-oxobutyl)benzene 
• 900186-21-2 4,4'-(1,4-phenylene)dibutyl dimesylate 
• 900186-26-7 6,6'-(1,4-phenylene)bis[2-(methylthio)hexanal] 
• 900186-19-8 6,6'-(1,4-phenylene)bis[2-(dimethylsulfanylidene)hexanal] 
• 85784-85-6 1,4-bis<4-(2-formylphenoxy)butyl>benzene 
• 6544-06-5 <12>paracyclophane 
• 134520-11-9 6,6'-p-phenylene-di-hexanoic acid 
• 201138-69-4 6,6'-p-phenylene-di-hexanoic acid dimethyl ester 
• 343588-18-1 1,4-bis-(5,5-dicarboxy-pentyl)-benzene 

Relevant articles and documents

FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

Synthesis of strapped porphyrins: Toward isolation of the chromophore on semiconductor surfaces

Figure presented Strapped porphyrins, designed to bind planar to semiconductor surfaces, were synthesized as model dyes to study the sensitization processes on metal oxide semiconductor nanoparticles surfaces. The strap was added to limit porphyrin-porphy

Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation

A series of conformationally restricted bis-azaaromatic quaternary ammonium salts (3 and 4) have been designed and synthesized in order to investigate the possible binding conformations of N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB; 2), a

Synthesis of planar-chiral paracyclophanes via samarium(II)-catalyzed intramolecular pinacol coupling

(Chemical Equation Presented) A series of [n]jparacyclophanediols (n = 8-12) was synthesized by samarium-catalyzed pinacol coupling for their ansa-bridge formation. Enantiomerically pure [n]jparacyclophane esters were derived from the diols in a several steps via chiral resolution (for n = 10) or via crystallization-induced asymmetric transformation (for n = 11) by using amino alcohol auxiliaries and their selective cleavages.

Mono- and bis-thiazolium salts have potent antimalarial activity

Three new series comprising 24 novel cationic choline analogues and consisting of mono- or bis (N or C-5-duplicated) thiazolium salts have been synthesized. Bis-thiazolium salts showed potent antimalarial activity (much superior to monothiazoliums). Among them, bis-thiazolium salts 12 and 13 exhibited IC50 values of 2.25 nM and 0.65 nM, respectively, against P. falciparum in vitro. These compounds also demonstrated good in vivo activity (ED50 ≤ 0.22 mg/kg), and low toxicity in mice infected by Plasmodium vinckei.

Both-faces Hindered Porphyrins. Part 1. Synthesis and Characterization of Basket-handle Porphyrins and Their Iron Complexes

The synthesis of the 'both-faces' hindered porphyrins using two different methods is reported.These so-called 'basket-handle' porphyrins (BHP) are derived from 5,10,15,20-tetraphenylporphyrin in which two opposite phenyl groups are bridged by alkylene or arylene-p-bisalkylene chains.In addition to the desired compounds , two other isomers were obtained .These were separated by t.l.c. on silica gel and then individually characterized.The structural assignment of the three isomers in the five series studied was based on the 1H n.m.r. spectra of the free bases and of their iron(II) complexes.